Richard Steven Levy
Independent DirectorDr. Richard Steven Levy, also known as Rich, M.D., is Director of Merida Biosciences. Dr, Levy served as an Independent Director of Constellation Pharmaceuticals, Inc. since April 3, 2020 until July 15, 2021. He serves as an Independent Director of Kiniksa Pharmaceuticals International, plc (formerly known as Kiniksa Pharmaceuticals, Ltd.) since March 4, 2019. He has been Independent Director at Madrigal Pharmaceuticals, Inc., since August 11, 2016. He has been a Director of Kodiak Sciences Inc. since June 2018. He was a part-time Senior Advisor for Baker Brothers Advisors, L.P. from December 2016 to May 2019, a firm that primarily manages long-term investment funds focused on publicly traded life sciences companies and as a part-time Advisor for Incyte Corporation, a publicly-held biopharmaceutical company. Dr. Levy also served on the Board of Directors of Neoleukin Therapeutics, Inc. (Formerly known as Aquinox Pharmaceuticals, Inc.) from March 2017 until March 2019 and Gliknik Inc., a privately-held biotechnology company. Previously, Dr. Levy served as CMO and also Executive Vice President and Chief Drug Development Officer at Incyte Corporation from January 2009 until his retirement in June 2016 and as Senior Vice President of Drug Development from August 2003 to January 2009. Prior to joining Incyte, Dr. Levy served as Vice President, Biologic Therapies, at Celgene Corporation, a publicly-held biopharmaceutical company, from 2002 to 2003. From 1997 to 2002, Dr. Levy served in various executive positions with DuPont Pharmaceuticals Company, first as Vice President, Regulatory Affairs and Pharmacovigilence and thereafter as Vice President, Medical and Commercial Strategy. Dr. Levy served at Novartis and its predecessor company Sandoz, from 1991 to 1997 in positions of increasing responsibility in clinical research and regulatory affairs. He served as a Director of ArTara Therapeutics, Inc. from December 2019 until January 2020. He has been an Independent Director at Protara Therapeutics, Inc. (Formerly known as Proteon Therapeutics Inc. since January 2020. Dr. Levy has experience in the pharmaceutical and biotechnology industries through his prior positions at Celgene, DuPont Pharmaceuticals and Novartis, has extensive clinical research, regulatory and product development skills and has worked in multiple therapeutic areas. Prior to joining the pharmaceutical industry, Dr. Levy served as an Assistant Professor of Medicine at the UCLA School of Medicine. Dr. Levy is Board Certified in Internal Medicine and Gastroenterology and received his A.B. in Biology from Brown University, his M.D. from the University Of Pennsylvania School Of Medicine and completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and a fellowship in Gastroenterology and Hepatology at UCLA.
Positions
- Company NameMadrigal Pharmaceuticals, Inc.Stock CodeMDGLPositionIndependent DirectorColleagues
- WJWilliam J. SiboldCEO, President & Director
- JCJulian Charles BakerIndependent Chairman of the Board
- RARebecca A. TaubFounder, Senior Scientific & Medical Advisor and Director
- MCMardi C. DierExecutive VP & CFO
- SKShannon KelleyExecutive VP, Chief Legal Officer & Corporate Secretary
- CHCarole HuntsmanExecutive VP & Chief Commercial Officer
- DJDaniel J. BrennanIndependent Director
